Oncolytics Biotech Inc. filed a current report on November 12, 2026, disclosing a clinical supply agreement announced on November 11, 2026, with Coherus Oncology, Inc. to support a clinical study focused on second-line squamous cell anal carcinoma patients at a premier cancer center in the United States.

Key Highlights

  • New agreement: Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology, Inc., according to the filing.
  • Target indication: The agreement is tied to a clinical study of second-line squamous cell anal carcinoma patients, as disclosed by the company.
  • Study site: The clinical study is planned at a premier cancer center in the United States, per the filing.
  • Announcement date: The company issued a press release on November 11, 2026, to publicly disclose the agreement.
  • Signing authority: The current report was signed by Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc.

Oncolytics and Coherus Oncology Agree on Clinical Supply for Anal Carcinoma Research

According to the filing, Oncolytics Biotech Inc. (NASDAQ:ONCY), a Nevada-incorporated biopharmaceutical company headquartered in San Diego, California, issued a press release on November 11, 2026, disclosing that it had entered into a clinical supply agreement with Coherus Oncology, Inc. The agreement relates to a clinical study targeting patients with second-line squamous cell anal carcinoma, an indication the company is pursuing at a premier cancer center in the United States.

The company disclosed the agreement under Item 8.01, covering other events, and noted that the information furnished in that item and in the accompanying Exhibit 99.1 press release "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." Oncolytics Biotech's common stock carries a par value of $0.001 per share and is listed on The Nasdaq Stock Market LLC under the symbol ONCY, as stated in the filing's registered-securities table.

The report was signed on behalf of Oncolytics Biotech Inc. by Kirk Look in his capacity as Chief Financial Officer. No financial terms of the clinical supply agreement were included in the current report filing itself; those details, to the extent publicly available, would be contained in Exhibit 99.1, the full text of the press release dated November 11, 2026.

What Was Disclosed

Oncolytics Biotech Inc. reported a clinical supply agreement with Coherus Oncology, Inc. for a study of second-line squamous cell anal carcinoma patients at a United States cancer center, announced via press release on November 11, 2026, and signed by CFO Kirk Look.